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ABSTRACT 
Tuberculosis (TB) is the leading cause of death from infection worldwide killing 
1.4 million people in 2015. There is an urgent need for shorter TB treatment but a major 
impediment to TB drug trials is lack of early surrogate outcomes. Existing surrogate 
endpoints are cultured-base and poorly predictive of treatment failure and relapse. My 
thesis analyzed data from a proof-of-concept study of a novel molecular marker of 
treatment effect: the ratio of bacterial precursor-ribosomal RNA to total 23S rRNA (pre-
rRNA/23S). Pre-rRNA/23S measures the rate of Mycobacterium tuberculosis (Mtb) 
replication in sputum. We tested the association of pre-rRNA/23S (ETS1/23S and 
ITS1/23S) with two existing culture-based surrogate markers: culture positivity and time 
to detection (TTD). The association of pre-rRNA/23S with culture positivity and TTD 
was estimated using logistic and linear mixed-effects regression models, respectively, in 
the SAS NLMIXED procedure to account for repeated measures on the same subject. Pre-
rRNA/23S was highly associated with culture positivity and TTD. Adjusted for Mtb 
burden, pre-rRNA/23S was independently associated with both culture positivity and 
TTD. These results provide important preliminary evidence that measurement of 
precursor ribosomal RNA provides biologically meaningful information about drug effect 
in human TB. 
The form and content of this abstract are approved. I recommend its publication.  
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Tuberculosis (TB) is the leading cause of death from infection worldwide, causing an 
estimated 1.4 million TB deaths in 2015[1]. TB treatment is long (6-9 months) and 
burdensome to both the patient and the health care system. There is an urgent need for 
new shorter TB treatment regimens. Unfortunately, drug trials are impeded by a lack of 
early surrogate markers for treatment failure or relapse. Currently, the surrogate marker 
used as a primary outcome in Phase IIb clinical trials is continued growth of 
Mycobacterium tuberculosis (Mtb) in sputum culture on Löwenstein–Jensen (LJ) solid 
medium after two months of treatment [2,3]. However, a series of studies have shown that 
positive sputum culture after two months of treatment is poorly predictive of treatment 
relapse (meaningful clinical outcome for patient care and TB drug trials). This presents a 
major barrier for the development of new TB drugs [3–5]. An alternative culture-based 
marker for TB treatment response is time to detection (TTD). Chapter II will review 
existing and candidate surrogate markers for treatment response in TB. This thesis 
evaluates a novel molecular approach for assessing TB treatment response based on 
quantification of precursor ribosomal RNA (pre-rRNA), a marker of rRNA synthesis. In 
bacteria, 16S, 23S and 5S rRNAs are co-transcribed on a polycistronic pre-rRNA 




Figure 1. ETS1 & ITS1 in the Mtb ribosomal operon. 
Pre-rRNA is transiently present during rRNA synthesis [6]. Since ribonucleases 
rapidly trim and degrade ETS1 and ITS1 to form mature rRNA, presence of pre-rRNA is 




time polymerase chain reaction (qRT-PCR). This molecular technique can be designed to 
exclusively target ETS1 and ITS1 regions in the pre-rRNA sequence. Our novel approach 
measures the ratio of pre-rRNA to total rRNA (pre-rRNA/23S). Chapter II will review the 
biological basis of pre-rRNA monitoring and experimental evidence suggesting that pre-
rRNA/23S (ETS1/23S & ITS1/23S) can predict treatment response in TB. Preliminary 
analyses suggest an association between pre-rRNA/23S and Mtb growth in culture. This 
implies a potential new pathway associated with sputum culturability during TB 
treatment. In this thesis, we also illustrate a novel factor of culturability: the growth state 
at the time of sputum collection. 
Development of novel surrogate markers is a long-term, multi-step process [7], 
culminating in validation in large-scale clinical trials. Our novel approach based on pre-
rRNA abundance is at an early stage of development. The over-arching aim in this thesis 
was to determine whether pre-rRNA/23S is associated with existing (suboptimal) culture-
based surrogate markers. This sets the groundwork for our novel pre-rRNA measure as 
potential TB biomarker. A secondary aim is to determine if pre-rRNA/23S provides 
additional information on sputum culture beyond that provided by burden alone. The 
conventional wisdom in TB research is that sputum culture is a measure of Mtb burden in 
culture; as treatment reduces Mtb burden, Mtb grows more slowly (or not at all). (Figure 
2, pathway 1). Our novel hypothesis is that Mtb replication rate (as measured by pre-
rRNA/23S) also influences growth in culture; as treatment slows Mtb replication, Mtb 






Figure 2. Conceptual diagram illustrating different pathways through 
which TB treatment may influence Mtb growth in culture. 
 
Specific Aims 
Aim 1: Describe changes in absolute and relative abundance of pre-rRNA (ETS1, ITS1) 
among successfully-treated TB patients. 
Aim 2: Determine whether pre-rRNA/23S is associated with sputum culture positivity 
among successfully-treated TB patients. 
Hypothesis 2: Sputum samples with higher pre-rRNA/23S – indicating active Mtb rRNA 
synthesis – will be associated with increased odds of culture positivity. Conversely, 
sputum samples with lower pre-rRNA/23S – indicating “dormant” Mtb population with 
suppressed rRNA synthesis – will have lower odds of culture positivity, even after 
controlling for abundance on Mtb measured by 23S. 
Aim 3: Determine whether pre-rRNA/23S is associated with TTD among successfully-
treated TB patients. 
Hypothesis 3: Sputum samples with higher pre-rRNA/23S will be associated with shorter 
TTD of Mtb growth in liquid culture. Conversely, sputum samples with lower pre-
rRNA/23S will have a greater TTD of Mtb growth in liquid culture, even after controlling 






Phases of TB Treatment 
During treatment of drug-susceptible TB, Mtb is killed in two distinct phases: 
bactericidal and sterilizing phases. In the initial 3-5 days “bactericidal” phase, >99% of 
Mtb in sputum are killed [7,8]. During the subsequent 6-month long “sterilizing” phase, 
residual subpopulations of Mtb bacilli, referred to as “persisters”, survive prolonged 
antibiotic exposure. Persistence is a fundamental issue in TB and explains the long 
duration of TB treatment. Genetically drug-susceptible yet phenotypically drug-tolerant 
Mtb persister bacilli are primarily linked to treatment failure and relapse [9,10]. 
Unfortunately, there is no good surrogate marker of TB treatment response for assessing 
how Mtb populations are affected by TB drugs. A surrogate marker is defined as “a 
laboratory measurement or a physical sign used as a substitute for a clinically meaningful 
endpoint – so changes induced by a therapy on a surrogate marker  are expected to reflect 
changes in a clinically meaningful endpoint” [10]. 
Approaches for Monitoring TB Treatment 
A number of different surrogate markers of TB treatment response exist.  
Broadly, these fall into three categories: measures of Mtb burden, measures of Mtb 
physiologic state, and measures of host immune response.  The current state of 
approaches within each of these categories is discussed below.   
Measures of Bacterial Burden 
Most markers that have been proposed as potential surrogates for treatment 
failure or relapse are measures of the burden of Mtb present in sputum.  This section will 
first discuss culture-based measures, then measures of Mtb nucleic acid burden, and 




Culture-Based Measures of Bacterial Burden 
Sputum culture status on solid media (LJ) after two months of therapy is the 
most widely used surrogate marker to assess efficacy in phase IIb clinical trials for the 
development of new TB drugs. Sputum culture status after two months of treatment is 
also used for monitoring treatment response in TB patients. An alternative culture-based 
approach that has been proposed but has not been validated yet is TTD, a measure of 
growth of Mtb in liquid medium Mycobacteria Growth Indicator Tube (MGIT). TTD 
measures how fast it takes a sputum sample to grow in culture. A sputum sample with 
high bacterial burden will have a shorter TTD, meaning that such a sample will take less 
time to grow in culture. In contrast, a sputum specimen with low bacterial burden will 
have a longer TTD, meaning that such a specimen will take longer to grow in culture. 
TTD has been found to correlate with response to treatment for pulmonary TB in several 
studies [11–13] but is not established as a surrogate marker.  
Although culture-based measures are ssociated with TB treatment outcomes, 
the strength of this association is limited, meaning they have limited ability to predict 
treatment failure and relapse [14,15].  A systematic review of 28 TB studies found that 
positive sputum culture after two months of treatment had a low sensitivity (40%, 95% 
CI: 25–56) to predict treatment failure or relapse [16]. This implies, of the people who 
relapsed only 40% had a positive sputum culture after two months of treatment. That 
same systematic review found positive sputum culture after two months of treatment to 
have a very low positive predictive value (18%) in predicting treatment failure or relapse, 
suggesting that among people who had a positive culture after two months of treatment, 
only 18% relapsed after treatment completion.  
There are several practical disadvantages to culture-based surrogate markers. 




early in treatment [17,18]. A negative sputum culture result does not necessarily mean 
absence of Mtb in sputum since bacteria may be present but below the limit of detection. 
Second, sputum culture methods are time-consuming and technically demanding. Sputum 
culture is therefore not widely available in high-burden settings [19]. In addition, sputum 
culture methods are labor intensive, slow and may take up to two months to provide 
results. Third, all culture-based methods are prone to contamination with other 
microorganisms present in a sputum sample [19,20]. Finally, several studies suggested 
that the presence of a significant proportion of viable but non-culturable Mt  populations 
in sputum [21,22]. 
Nucleic Acid-Based Measures of Bacterial Burden 
Mtb burden has also been quantified by measurement of nucleic acids such as 
rRNA or DNA. Honeyborne et al. proposed the molecular bacterial load (MBL) assay as 
a measure of mycobacterial 16S rRNA during TB treatment [20,23]. MBL provides 
information on Mtb viability during treatment, and MLB at day 0 was suggested to 
predict relapse. Mycobacterial DNA quantification expressed as cycle threshold (CT) 
values via Xpert MTB/RIF assay has also been proposed to be a useful tool for 
monitoring treatment effect [24,25]. However, it is unclear how this technique can be 
used to predict relapse given its inability to differentiate between DNA from dead and 
live Mtb. Both MBL and Xpert MTB/RIF assays have technical advantages over culture-
based markers as their results can potentially be obtained within 24 hours of sputum 
samples processing. Even though our novel marker is also based on the quantification of 
nucleic acids, our approach is different. MBL and Xpert MTB/RIF ascertain the burden of 
mycobacterial rRNA and DNA during treatment. However, our proposed marker will 





Limitations of Monitoring Bacterial Burden 
Regardless of the specific disadvantages mentioned above for each type of 
measure of Mtb burden, there are several limitations inherent to all measures of bacterial 
burden. First, sputum is an inherently variable specimen. Sputum volume and quality is 
influenced both by a patient’s efforts in providing a good sputum sample and whether 
sputum-producing cavities in lungs happen to be open at the time of collection. Second, 
variation in bacterial burden measurements increases with time on treatment and makes 
treatment effects on Mtb populations harder to measure [26]. Third, relapse is determined 
by drug activity against slow replicating Mtb populations (persisters). Since Mtb burden 
in sputum typically decreases >99% within the first week of treatment, measures of 
burden primarily reflect the effectiveness of early bactericidal killing rather than 
sterilizing effect of TB drugs [9,25].  
Measure of Bacterial Physiologic State 
An alternative to measuring burden is measuring the impact of treatment on the 
physiologic state of the bacterial population. Different staining techniques followed by 
viability assessment of acid fast bacilli (AFB) via fluorescent microscopy have been 
proposed as surrogate markers for TB treatment response. For instance, percentage 
change in the relative abundance of AFB was suggested to predict relapse [27,28]. 
However, these assays are not applicable to AFB negative sputa, cannot differentiate 
between mycobacteria species, need at least 10,000 AFB/ml to be positive, cannot 
distinguish between viable and dead organisms, and cannot distinguish between Mtb and 
non-tuberculosis mycobacteria [26,29].  Our approach based on pre-rRNA is a measure of 







Host-based markers include: radiological (chest radiograph, ultrasound, PET) 
and immune (cytokines or C-reactive protein) markers. Radiological markers are subject 
to inter-observer variability, expensive, and may expose TB patients to unnecessary high 
levels of radiation. On the other hand, immune markers are not specific to TB infection 
and have no specific thresholds [26].  
Description of the Novel Molecular Approach 
Ribosomal RNA Synthesis in Bacteria 
A bedrock microbiologic principle is that rRNA synthesis indicates bacterial 
growth and replication [30,31]. When bacteria are growing, replicating, or dividing they 
require more rRNA. An important aspect of rRNA synthesis in bacteria is that all three 
ribosomal RNA are transcribed together on a single transcript. This single-stranded rRNA 
molecule has the mature sequence for 16S, 23S and 5S rRNA. Between the mature rRNA 
sequence, there are short sequences called internal and external transcribed spacers. Once 
transcribed, the single-transcript is spliced into pre-RNA sequences, which in turn are 
processed into mature rRNA after the internal and external transcribed spacers are 
trimmed off (Figure 3). 
 
 
Figure 3. Ribosomal RNA synthesis and maturation in bacteria (Source: Gerard A. 





Proposed New TB Biomarker 
We intended to measure the relative abundance of pre-rRNA to 23S total rRNA. 
In this study both ETS1/23S and ITS1/23S were quantified using qRT-PCR. We believe 
these two biomarkers are different measures of the same biological process, rate of de 
novo rRNA synthesis. Previous methods have been based on qualitative detection of 
rRNA as measures of Mtb viability. Our innovation is quantification of pre-rRNA during 
treatment.  
Rationale for Testing pre-rRNA/23S as TB Surrogate Marker 
Association of pre-rRNA/23S with Mtb Replication 
A core microbiologic principle is that rRNA synthesis is directly correlated with 
bacterial replication [31]. Our experimental data suggest that pre-rRNA/23S is a valid 
measure of Mtb replication. Our collaborator, Dr. Martin Voskuil, demonstrated this in 
vitro by modulating Mtb growth with variable oxygen availability. Pre-rRNA/23S was 
highly correlated with growth rate (correlations of 0.94 and 0.86 for ITS1/23S and 
ETS1/23S, respectively) (Figure 4). 
 
Figure 4. ITS1/23S correlation with growth rate in Mtb with variable O2. 
 
Effect of Antibiotic Exposure on pre-rRNA/23S 
Dr. Voskuil conducted a series of in vitro experiments that demonstrate the 




part of the current global standard TB regimen, profoundly decreased pre-rRNA/23S 
(Figure 5). As shown in RNAseq data, rifampin exposure decreased ETS1/23S and 
ITS1/23S >100-fold relative to drug-unexposed control (Table 1). This extremely strong 
rifampin effect in vitro led to our hypothesis that pre-rRNA/23S may be a useful marker 
in humans. 
 
Figure 5. Integrative Genomics Viewer (IGV) screenshot of RNAseq data from in 
vitro drug exposures. Dotted lines mark ETS1, 16S, ITS1 & 23S sequences. Pink lines 
denote individual reads. Pre-rRNA was present in log phase drug-unexposed control 
(a) indicating ongoing rRNA synthesis. Mtb that survived 48h of lethal rifampin (b). 
 
Table 1. RNAseq results. Normalized Mtb ETS1, ITS1, and 23S counts during highly 
lethal in vitro drug exposure illustrate marked decline in ETS1 and ITS1 with 




 Day 2 Day 4 
Transcripts per Million (TPM) 
23S 530,225 624,759 693,196 
ETS1 27,258 58 30 
ITS1 24,695 72 235 
Pre-rRNA/23S (x 104) 
ETS1/23S 514 0.92 0.44 
ITS1/23S 466 1.15 3.39 
 
In summary, there is a critical need for novel surrogate markers of treatment 
response in TB. Given the poor sensitivity and positive predictive value of culture status 




promising alternative because of its long-term detection phase and as it is a measure of 







Specimens were collected through an observational biomarker study called 
STOP MTB.   STOP MTB was a sub-study of US Centers for Disease Control and 
Prevention TB Trials Consortium (TBTC) Study 36, a prospective observational study 
that enrolled and followed individuals with culture-confirmed rifamycin-sensitive TB. 
The objective of TBTC Study 36 was to determine the optimal methods for detection and 
quantification of Mtb in sputum over the course of TB treatment. The objective of STOP 
MTB was to evaluate transcriptional biomarkers in RNA extracted from sputum.  Both 
TBTC Study 36 and STOP MTB were conducted in accordance with national and/or local 
Institutional Review Board (IRB) and International Ethics Committee (IEC) 
requirements. Participants provided written informed consent for use of specimens for 
biomarker studies. STOP MTB enrolled adults ≥18 years of age with sputum AFB smear-
positive drug-susceptible TB who had not yet initiated treatment.   
Sputum Collection and Procession Procedures 
Serial sputa were obtained from 28 Vietnamese patients who initiated treatment 
with a standard regimen of isoniazid, rifampin, ethambutol, and pyrazinamide. Sputum 
specimens were collected at baseline (D0) before treatment started, and at day 1 (D1), 
week 1 (W1), week 2 (W2), week 4 (W4), week 6 (W6), week 8 (W8), week 13 (W13), 
and week 17 (W17), after treatment started. For each time point, two samples were 
collected from all participants. One was collected into a RNAase-free cup and the other in 
a cup containing 20mL of RNA preservation reagent, respectively. Clinical data used in 
this thesis involved microbiologic and molecular data. For microbiologic data, bacillary 




collected onsite at the Vietnam National Lung Hospital. All RNA-preserved samples were 
locally processed, frozen, stored and batch shipped to UCSF/Stanford University. 
Extraction of Mtb RNA was performed at Stanford University using well established and 
validated Mtb multiplex qRT-PCR assay that employs TaqMan to quantify Mtb-specific 
rRNAs. The following results were available: 
• sputum AFB culture result in LJ; A categorical variable expressed as positive, 
negative, contamination; 
• sputum AFB culture results in MGIT; A categorical variable expressed as 
positive, negative, contamination; 
• TTD in MGIT; A continuous variable expressed in days; 
• Cycle threshold (CT) values; A continuous and dimensionless variable 
expressing the abundance of ETS1, ITS1, and 23S from qRT-PCR. Higher CT 
values indicate lower abundance of the sequence of interest. 
Variables of Interest 
Primary explanatory variables 
ETS1/23S and ITS1/23S are different measures of the same biologic process. 
They measure the rate of de novo rRNA synthesis which is closely associated with 
bacterial replication. Specifically, how CT values are used to calculate ETS1/23S and 
ITS1/23S is explained in detail in Appendix A: Calculation of ETS1/23S and ITS1/23S. 
Covariate 
23S rRNA provides a measure of Mtb burden in sputum and was used as 
covariate in our statistical models. We chose 23S rRNA because preliminary data suggest 







For Aim 2, a composite culture variable (positive/negative) that combines LJ and 
MGIT culture results was created for Aim 3 TTD in MGIT was the primary outcome. 
Methodological Challenges 
Discussion of Culture Data for Aim 2 
The microbiologic dataset has several distinct types of information including 
positive, negative, contaminated, and not collected results. (Table 2). We combined LJ 
and MGIT results to create a composite culture variable (see details in Appendix B: 
Composite Culture). The composite culture approach has been previously implemented 
for the assessment of DNA assay as an early sputum biomarker of TB treatment response 
[19]. A positive result indicates Mtb was grown in either LJ or MGIT and a negative result 
indicates Mtb was below the detection threshold, not necessarily that Mtb was absent. A 
contaminated result indicates overgrowth with rapidly growing mouth flora, and does not 
provide information on whether the culture would have been positive or negative and was 
therefore considered missing. 
Discussion of Culture Data for Aim 3 
The primary outcome for Aim 3 is TTD. TTD is right-censored. A negative 
result in MGIT provides important information, as it indicates bacterial growth was below 
the detection threshold. Negative results in MGIT were censored on the 42nd day without 









Table 2. Summary of the composite culture variable. Rows represent individual 
patient IDs. Columns represent samples from different time points. Cells colored 
green indicate samples with positive culture results. Cells colored blue indicate 
samples with negative culture results. Cells colored white indicate samples with 
contaminated results. Cells colored gray indicate no sample collected. 
 
 
Table 3. Summary of TTD in MGIT. Rows represent individual patient IDs. 
Columns represent samples from different time points. Cells colored green indicate 
samples with positive MGIT results for which TTD was estimated. Cells colored blue 
indicate samples with negative MGIT results for which TTD was censored. Cells 
colored white indicate samples with contaminated MGIT results. Cells colored gray 
indicate no sample collected. 
 





























id D0 W2 W4 W6 W8 W13 W17
36-37-00087 5.5 12.5 15 9.21 16.17 13.17
36-37-00090 3.62 6.88 9 15.25 16.96 31.21
36-37-00107 4.54 9.33 18.17 39.29 28.88
36-37-00110 5.33 11 27.12
36-37-00113 8.83 9 25.71
36-37-00119 4.67 8.96 14.58 17.75 18.29 23.54
36-37-00120 5.75 21.12
36-37-00128 4.29 13.08 15.71 33.96
36-37-00129 4.29 10.04 17.5 28
36-37-00136 1
36-37-00159 7.58 13.12 24.79
36-37-00169 5 7.75 10.62 19.46
36-37-00172 5.92




36-37-00195 3.79 5.46 14.79
36-37-00203 4.96 6.58 10 12 6.33
36-37-00211 4.88 9 23 25.21
36-37-00217 3.46 10.75 15.96 20.04 6.71
36-37-00223 3.04 12.46 15.25
36-37-00227 4.5 9.62 16.71 14.54 15.92 9.21
36-37-00230 6.12 26.17
36-37-00231 3.33 12 15.33 30
36-37-00237 7.67
36-37-00247 4.42 16.29 15.5 30.04




Discussion of rRNA Data 
CT values indicate detection and abundance of rRNA sequences. CT measures 
of pre- and total rRNA were right-censored. CT values are inversely proportional to 
rRNA abundance. A positive result (CT<35) indicates detection of the sequence of 
interest. Failure to detect the sequence indicates that the abundance of the sequence is 
below the limit of detection (LOD), not necessarily that the sequence is absent. In 
addition, some rRNA CT results were missing because sputum samples were not 
collected at those time points. Conceptually, there are two distinct processes that may 
lead ETS1 and ITS1 to become undetectable. First, the burden of Mtb and all Mtb nucleic 
acids declines with treatment. 23S rRNA is many times more abundant than pre-rRNA 
(ETS1, ITS1). Therefore, even if pre-rRNA and 23S decline “in parallel” (i.e., there is no 
change in the ratio of pre-rRNA to 23S rRNA), ETS1 and ITS1 drop below the LOD 
earlier than 23S (Figure 6a). Second, ETS1 and ITS1 may decline more rapidly than 23S. 
Thus, for a given level of 23S, ETS1 and ITS1 sometimes becomes non-detectable with 
progressive time on treatment. This phenomenon is illustrated in Figure 6b.  
 
Figure 6. Conceptual diagram of two distinct processes that may cause pre-rRNA 
(ETS1 or ITS) to become non-detectable. (a) pre-rRNA and 23S may decrease “in 
parallel.” Pre-rRNA becomes non-detectable sooner simply because it is less 
abundant. (b) pre-rRNA may decrease faster than 23S. 
 
The phenomenon in Figure 6b is also illustrated in Table 4. For a similar range 
of 23S (CT values 29.6 to 30.6), ETS1 and ITS1 more frequently drop below the LOD in 




pre-rRNA/23S, providing valuable information about the process of interest. Considering 
these values to be missing would result in the loss of this information. For the complete 
rRNA data, see details in Appendix C: Summary Tables of ETS1, ITS1, and 23S CT 
Values. 
Table 4. 23S, ETS1 and ITS1 CT values for selected samples. 
ID Time 23S CT ETS1 CT ITS1 CT 
36-37-00230 Baseline 29.64 30.90 30.93 
36-37-00183 Baseline 29.74 31.97 31.86 
36-37-00113 Baseline 30.65 31.48 31.95 
36-37-00237 Day 1 29.88 33.37 33.72 
36-37-00183 Day 1 30.25 33.70 NA 
36-37-00231 Week 2 30.54 NA NA 
36-37-00169 Week 4 29.68 NA NA 
36-37-00159 Week 4 29.95 NA 31.67 
36-37-00217 Week 4 30.17 NA NA 
36-37-00223 Week 6 29.72 NA NA 
36-37-00247 Week 6 29.89 NA NA 
36-37-00211 Week 8 29.77 NA NA 
36-37-00128 Week 8 30.63 NA NA 
36-37-00120 Week 13 29.67 NA NA 
36-37-00217 Week 13 30.11 NA NA 
36-37-00087 Week 13 30.16 NA 33.78 
 
Approaches to Account for Censored Data 
Censoring in the Outcome 
To account for censored TTD values, we used a maximum likelihood (ML) 
method assuming a normal distribution for TTD [34]. For each subject, the contribution 
to the likelihood is a product of probability density functions for observed outcomes and 
cumulative density functions for censored outcomes, given the observed outcomes. 
Censoring in the Predictors 
Simple Substitution 
Censored observations were replaced by their corresponding LOD. This method 
is known to provide biased estimates and may result in to a loss of power. In addition, 
estimates of the mean tend to be larger while estimates of the standard deviation (SD) 






The second approach was to delete censored observations. Unbiased estimates 
can be obtained by simply discarding censored observations. However, in presence of 
small sample sizes, this method may provide biased estimates and may result in to a loss 
of power [35]. 
Richardson and Ciampi (RC) Method (Single Imputation) 
This method assumes the LOD is a constant and relies on a parametric 
assumption of normality [36]. We replaced censored pre-rRNA and 23S observations 
with their expected values given that observation was below the LOD [E(pre-rRNA| pre-
rRNA<LOD) and E(23S|23S<LOD)]. The RC method is a good approach to deal with 
censoring, as it provides consistent and relatively efficient estimates and is 
straightforward to implement in standard statistical software, such as SAS Proc Lifereg.  
Data Analysis Plan 
Data analyses were performed in SAS software version 9.4 (SAS Institute Inc., 
Cary, NC) for Windows and in R software version 3.3.3. A five percent (5%) significance 
level was used for inferential analyses. The nonlinear mixed model procedure 
(NLMIXED) in SAS was used to fit all models. ETS1/23S and ITS1/23S as well as the 
abundance of each rRNA sequence (23S, ETS1, and ITS1) were log10-transformed due to 
skewness. For details on all models, see Appendix D: Statistical Appendix. 
Analysis 1 for Aim 1 
 Describe the change in absolute and relative abundance of pre-rRNA over time 
using curves and summary statistics. 
Analysis 2 for Aim 2 
The association between pre-rRNA/23S and culture results was evaluated using 




positivity as a function of pre-rRNA/23S, adjusting for 23S. The models included a 
random intercept to account for correlation due to repeated measurements made on the 
subjects over time. 
Analysis 3 for Aim 3 
The association between pre-rRNA/23S and TTD was evaluated using linear 
mixed models. We modeled TTD as a function of pre-rRNA/23S, adjusting for 23S. A 
random intercept was included in the models to account for repeated measures made on 
the same subject over time. Right censoring of TTD data was accounted for using the 





EVALUATION OF TECHNIQUES TO ACCOUNT FOR CENSORING 
Summary of Predicted Values for Imputation 
After conversion from CT to relative gene copy number (RGCN) and log10-
transformation, the rRNA data were left-censored with LOD of 2.16, 1.63, and 1.61 for 
23S, ETS1, and ITS1, respectively. Using the RC imputation technique, predicted values 
for censored observations were estimated for every time point based on a normal 
parametric assumption and for each rRNA sequence. Predicted values for ETS1 and ITS1 
could not be estimated at Week 17 because all observations were censored (Table 5). 
Table 5. Summary of expected values for each time point for all rRNA 
sequences (23S, ETS1, and ITS1) given rRNA RGCN < LOD 
 log10(23S) log10(ETS1) log10(ITS1) 
Baseline 1.79 1.18 1.18 
Day 1 1.88 1.25 1.21 
Week 1 1.8 1.11 1.08 
Week 2 1.81 0.92 0.95 
Week 4 1.82 0.53 0.44 
Week 6 1.66 -0.22 0.27 
Week 8 1.67 -0.69 -1.08 
Week 13 1.75 -0.2 0.07 
Week 17 1.37 NA NA 
 
Summary of Means and Standard Deviations 
The means and standard deviations were estimated for each rRNA sequence 
using the three different techniques to account for censoring discussed above. As 
expected, of the three techniques the RC imputation approach was the most efficient 
because we were able to estimate observations below the LOD. Compared to the RC 
technique, the means for the substitution and the deletion techniques were overestimated, 
whereas their standard deviations were underestimated (Table 6). Simulation studies have 
shown that when the normal parametric assumption is correct, the RC technique shows 





Table 6. Summary of the means and standard deviations for all rRNA 
sequences (23S, ETS1, and ITS1), after the implementation of three 
different methods to address censoring in the rRNA data. 
 Substitution Deletion Imputation 
Mean SD Mean SD Mean SD 
log10(23S) 3.90 1.26 4.22 1.12 3.83 1.37 
log10(ETS1) 2.40 1.07 3.38 0.97 1.69 1.85 






ASSOCIATION OF PRE-RRNA/23S WITH CULTURE 
Descriptive Analysis 
Abundance of rRNA Sequences 
The abundance of 23S, ETS1, and ITS1 decreased over time, indicating 
decreasing abundance of all nucleic acids with treatment (Figure 7). Overall, ETS1 and 
ITS1 declined more rapidly than 23S, suggesting that rRNA synthesis slows down during 
TB treatment. 
 
Figure 7. Curves showing Change in 23S, ETS1 and ITS1 over 
time using Loess fit. 
  
Change in ETS1/23S and ITS1/23S 
ETS1/23S and ITS1/23S decreased with TB treatment (Figure 8). ETS1/23S and 
ITS1/23S showed similar patterns, supporting the assumption that they were two different 









Results for the Association of pre-rRNA/23S with Culture Positivity 
ETS1/23S and ITS1/23S were positively and significantly associated with 
culture positivity (p=0.0008 and p=0.0004, respectively). The strength of this association 
was reduced but still significant after controlling for Mtb burden (based on 23S copy 
number), suggesting an independent association of ETS1/23S and ITS1/23S with culture 
positivity (p=0.0102 and p=0.0324, respectively). In the crude models, the odds of culture 
positivity increased 2.7 times (exp[0.98]) for every log10 increase in ETS1/23S. Adjusted 
for 23S, the odds of culture positivity increased 2.3 times for every log10 increase in 
ETS1/23S. Similar trends were observed for ITS1/23S. The odds of culture positivity 
increased 2.7 and 1.8 for every log10 increase in ITS1/23S, in the crude and adjusted 






Table 7. Parameter estimates for the association between ETS1/23S and 
ITS1/23S with culture results. 
 
Models Parameter Estimate 
95% Confidence 











0.8418 0.2163 1.4673 0.0102 149.2 










0.5715 0.05161 1.0913 0.0324 153.3 
 
Results for the Association of pre-rRNA/23S with TTD 
ETS1/23S and ITS1/23S were negatively and significantly associated with TTD 
(p<.0001 and <.0001, respectively). The strength of this association was reduced but still 
significant after controlling for 23S, suggesting an independent association of ETS1/23S 
and ITS1/23S with TTD (p=0.0035 and p=0.0022, respectively). In the crude models, on 
average TTD decreased by 9 days for every log10 increase in ETS1/23S, whereas TTD 
decreased by 10 days for every log10 increase in ITS1/23S. Adjusted for 23S, on average 
TTD decreased by 4 days for every log10 increase in ETS1/23S and by 5 days for every 
log10 increase in ITS1/23S (Table 8). 
Table 8. Parameter estimates for the association between ETS1/23S and 
ITS1/23S with TTD. 
 
Models Parameter Estimate 
95% Confidence 











-4.3901 -7.2048 -1.5755 0.0035 871.4 

















Main Findings and Implications for TB Treatment Response Monitoring 
Among 28 Vietnamese patients treated for drug-susceptible pulmonary TB, we 
found that samples with higher pre-rRNA/23S were more likely to be culture positive and 
grew more quickly in liquid culture. These results affirm that our candidate marker – pr -
rRNA/23S – is associated with existing culture-based surrogate markers. They also 
support our secondary hypothesis that Mtb replication rate (as measured by pre-
rRNA/23S) influences Mtb growth in sputum culture.  
These results were consistent across two culture outcomes, suggesting high 
consistency. We also found similar patterns using two separate measures of rRNA 
synthesis rate (ETS1/23S and ITS1/23S), suggesting high internal validity. The strength 
of the association between pre-rRNA/23S and existing culture-based surrogate markers 
decreased after controlling for Mtb burden (characterized by 23S abundance). Therefore, 
these results suggest that both burden and replication state affect culturability. Our 
findings identify a new pathway associated with culturability. The determinants of 
whether Mtb grows in culture are complex and poorly understood. The burden of Mtb 
inoculated into culture is an obvious and intuitive factor. The type of culture media used 
and culture conditions are also a factor. Our study illustrates an additional novel factor – 
the growth state at the time of sputum collection.  
In this study, we have evaluated our candidate surrogate marker against a set of 
imperfect culture-based reference standards. Ideally, a perfect reference standard would 
have a 100% sensitivity and 100% specificity to predict relapse. While prolonged sputum 
culture positivity is associated with relapse, culture is poorly predictive of relapse. When 




biomarker as compared to this imperfect reference standard depends on errors in the 
imperfect reference standard itself rather than poor performance of the biomarker [37]. 
Our novel marker therefore cannot be validated by comparison with culture; the validity 
of our candidate surrogate marker will ultimately have to be demonstrated relative to the 
meaningful outcome itself, which is relapse.  Nonetheless, our demonstration of an 
association with the currently available reference standards (even though imperfect) was 
an important preliminary step in the development of a new TB biomarker.  
Previous studies suggested that pre-rRNA can be quantified as a measure of 
bacterial activity. Cubero et al., detectd he metabolic activity of viable but non-
cultivable bacilli among patients treated for latent TB infection by quantifying pre-rRNA 
[33]. Similarly, Cangelosi et al., measured the effects of in vitro antibiotic exposure on 
mycobacterial pre-rRNA [32]. However, none of these studies have tested pre-rRNA as a 
marker of treatment response. On the other hand, Honeyborne et al., tested 16S rRNA as 
a marker of treatment response but their work focused on measuring Mtb viability alone 
not on Mtb replication state [20,23]. The results in this thesis provide an important 
preliminary validation of pre-rRNA/23S as a novel marker. We also know that presence 
of phenotypically distinct Mtb populations in sputum as a direct result of variability in 
pharmacokinetic effects of TB drugs represents a limitation for culture-based measures. 
However, this in fact represents a strength for our novel marker because it has the 
potential of measuring the activity of both culturable and nonculturable Mtb populations 
in sputum. Unlike measures of Mtb burden, our novel marker presents several advantages: 
• pre-rRNA/23S measures a physiological parameter, the rate of de n vo rRNA 
(closely linked to Mtb replication); 
• pre-rRNA/23S has a longer detection phase (generally remains quantifiable 




• pre-rRNA/23S is less subject to sputum-to-sputum variability in Mtb content;  
• pre-rRNA/23S provides real-time information, as qRT-PCR results potentially 
obtained within hours. 
 Challenges and Limitations 
This thesis has several limitations. First, because of the small number of patients, 
we did not investigate covariates that could have potentially altered the relationship 
between pre-rRNA/23S and culture outcomes, such as HIV status, presence of pulmonary 
cavities and Mtb lineage. However, our results provide important preliminary evidence 
that measurement of pre-rRNA provides biologically meaningful information about drug 
effect in human TB. Association with clinical covariates will be explored in future 
studies. Second, culture and rRNA preservation are performed on separate sputa 
(collected on the same day), so variability between sputa could make it more difficult to 
identify associations between pre-rRNA and growth in culture. However, our preliminary 
results suggest that that this will not obscure a meaningful and consistent association. 
Finally, the fact that ETS1 and ITS1 go out of the detection range faster and earlier than 
23S was technically challenging. However, we successfully and efficiently estimated the 
predicted values of censored observations using the RC imputation technique. 
Next-Step Objectives 
An association with existing culture-based surrogate markers in this proof-of-
concept study was necessary to set the stage for our long-term objectives. Our next steps 
will be to test pre-rRNA/23S among patients enrolled in a large, international, 
randomized drug trial (ClinicalTrials.gov Identifier: NCT02410772) that compares 
efficacy of two high-dose rifamycin arms versus a standard control regimen. First, we 
will test whether pre-rRNA/23S is associated with pharmacokinetic parameters. We 




pre-rRNA/23S, indicating interruption of rRNA synthesis and replication. Second, we 
will test whether pre-rRNA/23S is associated with relapse. We hypothesize that higher 
pre-rRNA/23S – indicating ongoing rRNA synthesis and replication – will be associated 






In this thesis, we showed that pre-rRNA/23S declined among patients 
successfully treated with standard TB treatment. We also showed that pre-rRNA/23S is 
associated with existing culture-based surrogate markers, providing important proof-of-
concept support for our approach.   Finally, we identified a novel factor – bacterial 
replication in sputum – associated with sputum culturability. Development of novel 
accurate surrogate markers of treatment efficacy will accelerate TB drug development and 
improve routine patient care. This proof-of-concept study is a small piece of a large 
project to develop new markers for TB treatment response. Additional research is needed 
to fully understand the potential of our novel marker as surrogate for relapse in phase III 
clinical trials. We believe that higher pre-rRNA/23S – signaling continued rRNA 
synthesis – will be associated with increased relapse risk. If proven to be true, this will 
provide a new paradigm for sterilizing activity in TB, a potential change of enormous 
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Calculation of ETS1/23S and ITS1/23S 
CT values obtained through qRT-PCR assays provide a relative quantification of 
Mtb ribonucleic materials in sputum samples. These CT values were used to calculate 
relative gene copy numbers (RGCN), which in turn were used for the ratio calculations. 
Step 1: Transforming CT to RGCN 
Calibration was performed by determining the CTs of samples with known 
amounts of 23S, ETS1, and ITS1 copies (Table A1). Calibration curves were created for 
each rRNA sequence and the curves coefficients were used to transform clinical samples’ 
CT values into RGCNs (Figure A1). In these formulas, Y is the observed CT value. X is 
the calculated RGCN.  






23S ETS1 ITS1 
1.00E+03 31.96 30.24 30.24 
1.00E+04 28.46 26.57 26.57 
1.00E+05 24.72 23.19 23.02 
1.00E+06 21.21 19.66 19.76 
Calibration Equations y = -1.563ln(x) + 42.783 y = -1.526ln(x) + 40.725 
 
y = -1.519ln(x) + 40.64 
 
 
Step 2: Calculating ratios 
Since CT values were right-censored, the RGCNs calculated in step 1 were left-
censored. ETS1/23S and ITS1/23S were calculated based on the RGCNs in step1. The 
RGCNs were skewed, therefore were log10-transformed. For each sputum sample, ETS1, 













We created a composite LJ/MGIT culture result to address contaminate results 
and discordance between results obtained with LJ and MGIT culture methods. Results 
with LJ or MGIT alone are shown in Tables A2 and A3.  
Table A2. Summary of LJ results. Rows represent individual patient IDs. Columns 
represent samples from different time points. Cells colored green indicate samples with 
positive LJ results. Cells colored blue indicate samples with negative LJ results. Cells 










































Table A3. Summary of MGIT results. Rows represent individual patient IDs. Columns 
represent samples from different time points. Cells colored green indicate samples with 
positive MGIT results. Cells colored blue indicate samples with negative MGIT results. 
Cells colored white indicate samples with contaminated results. Cells colored gray 
indicate no sample collected. 
 
 
The discordance between MGIT and LJ as illustrated in Table A4, led us to 
create the composite culture variable shown in Table 1 above. The composite culture 
variable is defined as follow: when either culture result is positive, then the composite is 
positive. If both culture results are negative, then the composite is negative. If on  culture 
result is negative and the other is contaminated, then the composite is negative. Finally, if 
both culture results are contaminated, then the composite is contaminated.  
 
Table A4. Concordance/discordance between MGIT and LJ culture results for the 
same sputum specimens. 
  LJ Result  
Positive Negative Contamination 
MGIT 
Result 
Positive 68 27 7 
Negative 0 59 7 
Contamination 4 16 5 
 

































Summary Tables of ETS1, ITS1 and 23S CT Values 
Table A5. Summary of ETS1 abundance without imputation. Rows represent individual 
patient IDs. Columns represent samples from different time points. Cells colored green 
indicate samples in which both ETS1 and 23S were detectable. Cells colored blue 
indicate samples in which neither ETS1 and 23S were detectable. Cells colored yellow 
indicate samples in which ETS1 was not detected and 23S abundance was high (CT 
value <31). Cells colored brown indicate samples in which ETS1 was not detected and 
23S abundance was low (CT value >31). Cells colored gray indicate no sample 
collected. 
id D0 D1 W1 W2 W4 W6 W8 W13 W17
36-37-00087 25.63 25.91 28.99 29.3 32.15 31.61
36-37-00090 20.44 22.77 25.34 28.49 28.45 34.28
36-37-00107 28.11 29.98 32.63 32.29
36-37-00110 30.33 31.4
36-37-00113 31.39 31.44 31.52
36-37-00119 30.66 25.21 31.19 30.7
36-37-00120 28.05 24.8 28.77 29.27 31.98 33.89
36-37-00128 23.87 27.46 32.35 31.75 31.72
36-37-00129 22.73 25.63 26.62 33.22
36-37-00136 31 30.96
36-37-00159 26.1 24.79 27.79 33.04
36-37-00169 31.93
36-37-00172 28.12 29.91 32.17
36-37-00177 26.64 21.82 32.93 33.43 33.91
36-37-00183 31.86 33.57 32.16
36-37-00188 27.67 27.48 31.03 32 34.58
36-37-00190 25.32 30.18 28.9
36-37-00195 26.13 28.97 32.1
36-37-00203 20.25 23.33 28 30.09 32.03 29.23
36-37-00211 27.53 28.67 28.6 29.02 29.23 32.97
36-37-00217 23.19 24.81 28.85 30.55
36-37-00223 22.21 26.5 30.94 28.17 31.25
36-37-00227 22.33 25.16 30 28.67 32.24 29.12 30.98
36-37-00230 30.78 27.27 32.4 33.13
36-37-00231 25.88 29.93 27.1 32.48
36-37-00237 33.85 33.32
36-37-00247 26.1 28.89 32.48













Table A6. Summary of ITS1 abundance without imputation. Rows represent individual 
patient IDs. Columns represent samples from different time points. Cells colored green 
indicate samples in which both ITS1 and 23S were detectable. Cells colored blue 
indicate samples in which neither ITS1 and 23S were detectable. Cells colored yellow 
indicate samples in which ITS1 was not detected and 23S abundance was high (CT 
value <31). Cells colored brown indicate samples in which ITS1 was not detected and 
23S abundance was low (CT value >31). Cells colored gray indicate no sample 
collected. 
id D0 D1 W1 W2 W4 W6 W8 W13 W17
36-37-00087 25.5 26.52 27.95 28.06 29.05 29.31 33.69
36-37-00090 20.52 22.76 24.05 26.05 26.07 30.79 32.72
36-37-00107 27.08 29.7 32 33.11 32.24
36-37-00110 30.23 31.59 34.32
36-37-00113 31.84 30.34 31.87
36-37-00119 29.85 25.82 29.59 28.91
36-37-00120 28.28 24.97 27.05 26.67 29.54 31.22
36-37-00128 23.28 27.5 29.87 30.56 29.68
36-37-00129 22.23 25.26 26.03 33.46
36-37-00136 30.74 28.85
36-37-00159 24.9 24.3 24.94 30.93 31.56 30.63
36-37-00169 31.92
36-37-00172 28.01 29.85 30.69
36-37-00177 26.46 22.49 32.37 33.15 32.99 32.83
36-37-00183 31.73 30.48
36-37-00188 27.84 28.03 31.79 32.32 33.19
36-37-00190 24.72 29.29 34.43 28.35
36-37-00195 25.57 28.25 31.17 31.94 33.53 30.6 32.17 33.7
36-37-00203 20.32 23.27 28.02 29.3 31.05 28.29
36-37-00211 27.23 28.11 28.5 26.78 27.84 30.83
36-37-00217 22.75 25.06 28.52 28.68
36-37-00223 22.52 26.56 29.76 28.6 31.15
36-37-00227 21.98 25.12 29.17 28.26 31.67 29.01 31.08
36-37-00230 30.91 27.11 32.62 31.55
36-37-00231 25.53 29.6 26.64 33.23
36-37-00237 32.7 33.02
36-37-00247 26.26 28.69 30.27














Table A7. Summary of 23S rRNA abundance. Rows represent individual patient IDs. 
Columns represent samples from different time points. Cells colored green indicate 
samples with positive 23S results. Cells colored blue indicate samples in which 23S 




id D0 D1 W1 W2 W4 W6 W8 W13 W17
36-37-00087 23.41 22.8 24.51 25.37 26.58 26.29 32.15 30.08
36-37-00090 18.07 19.87 20.04 22.37 21.37 34.6 25.09 26.79 27.31
36-37-00107 25.97 23.58 25.01 27.08 29.31 27.87 32.4 34.59
36-37-00110 28.81 27.56 32.79 28 31.91 32.91 32.94
36-37-00113 30.63 28.5 33.07 27.8 30.96 32.93 33.19
36-37-00119 28.04 22.12 24.97 24.08 29.83 29.5 32.69 31.22 33.91
36-37-00120 26.98 24.48 25.58 24.51 25.66 26.36 31.93 28.96 30.68
36-37-00128 21.93 24.18 25.97 25.25 24.59 28.93 30.62 30.22
36-37-00129 21.49 20.98 19.9 31.47 30.65 31.1 33.09 32.75
36-37-00136 28.86 32.67 24.91 31.8 32.83 33.72 31.94 34.58
36-37-00159 23.96 22.37 24.32 28.89 29.89 26.82 31.94 32.89 34.27
36-37-00169 33.33 27.17 29.22 28.86 29.67 31.13 32.77 31.98
36-37-00172 24.74 23.92 32.35 34.01 32.17 31.49 26.6
36-37-00177 24.49 18.51 27.99 27.87 28.05 27.59 32.27 32.91 33.77
36-37-00183 29.5 30.23 26.48 31.48 30.7 33.54 31.03
36-37-00188 25.89 24.74 25.9 27.66 27.68 33.78 28.14 34.08
36-37-00190 23.29 24.91 29.9 30.66 24.82
36-37-00195 23.1 25.25 26.64 28.8 28.19 29.21 28.58 29.3 27.5
36-37-00203 17.58 19.08 23.29 24.8 25.46 24.04 31.55 31.6 32.93
36-37-00211 25.23 24.93 24.7 25.02 24.9 27.36 29.72 28.04 30.96
36-37-00217 20.59 18.92 21.69 21.74 30.03 31.1 30.02 31.96
36-37-00223 18.19 21.01 24.84 23.02 26.47 29.67 28.94 31.65
36-37-00227 20.88 23.23 23.93 23.12 26.76 25.54 28.47 34.2
36-37-00230 29.59 24.94 29.21 27.92 32.52 31.06 31.74 29.99
36-37-00231 22.56 22.08 25.95 30.46 30.71 28 32.44
36-37-00237 27.77 29.87 34.35 33.04
36-37-00247 24.65 27.17 27.51 32.39 32.39 29.78 29.31 33.93






SAS Codes for Lifereg Procedure to Adjust Means and SDs at each Time Point: 
##23S: This same code applies for ETS1 and ITS1 
data eachtimepoint_data; 
if log10RGCN_23S > 2.16 then lower = log10RGCN_23S; 
 else lower = .; run; 
proc lifereg data= eachtimepoint_data; 
 model (lower, Y) = / d=normal; 
run;  
SAS Codes for Aim 2 
**binary logistic regression (this code also applies for ITS1/23S ratio) **; 
**ETS1/23S adjusting for 23S abundance**; 
proc nlmixed data=work.imputation; 
parms b0=-0.7142 b1=0.404  b2=0 s2u=2; 
eta = b0 + u + b1*log10Ratio_ETS1_23S + b2*log10RGCN_23S; 
expeta = exp(eta); 
p = expeta/(1+expeta); 
model composite ~ binary(p); 
random u ~ normal(0,s2u) subject=id; run; 
SAS Codes for Aim 3 
**Mixed effects regression (this code also applies for ITS1/23S ratio) **; 
**ETS1/23S adjusting for 23S abundance**; 
proc nlmixed data=work.imputation tech=nrridg; 




mu = beta0 + a + beta1*log10Ratio_ETS1_23S + beta2*log10RGCN_23S;   
Z = (TTD - mu)/sqrt(s); 
if coding = 1 then ll = -(log(2*3.14159)+log(s)+Z**2)/2; *uncensored; 
else if coding = 2 then ll=log(1-probnorm(Z)); * right censoring; 
model TTD~general(ll);  
random a ~ normal(0, g11) subject=id;  
ODS OUTPUT ParameterEstimates = accountboth;  
run; 
